There are substantial healthcare costs associated with the provision of renal replacement therapy. Patients with diabetes mellitus are the largest and fastest growing group developing end-stage renal disease (ESRD) in the United Kingdom (UK). Treatment leading to a slowing of progression to ESRD in diabetic patients could lead to considerable cost savings. Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model. UK-specific ESRD-related data were retrieved from published sources to reflect local management practices, ESRD outcomes and costs. Mean 10-year costs and changes in life expectancy due to ESRD delayed or avoided were calculated. Future costs and clinical benefits were discounted at 6.0 and 1.5% per annum and extensive sensitivity analyses were performed. Delay in the onset of ESRD with irbesartan led to cost savings of d5125 and d2919/patient and improvements in projected discounted life expectancy of 0.07 and 0.21 years over 10 years vs amlodipine and control, respectively. The costs of treatment of ESRD were the main contributor to the total costs. The cost of trial medications had only a minor impact. These results were robust in a wide range of plausible assumptions. Given that the IDNT efficacy results could be translated to a UK setting, treating patients with hypertension, type II diabetes and overt nephropathy with irbesartan was cost saving over a 10-year period compared to amlodipine and control.
Introduction
In Europe, 3-35% of patients with type II diabetes have nephropathy. These patients represent the largest and fastest growing single disease group requiring renal replacement therapy (RRT). In addition to the high risk of progression to end-stage renal disease (ESRD), diabetic nephropathy is also associated with an increased risk of cardiovascular morbidity and mortality. 1 Diabetic nephropathy is now the commonest single cause of ESRD in the UK, with 24% of new ESRD patients having diabetes as a comorbidity factor. 2 Overall, new cases of ESRD due to diabetes, hypertension and renal vascular disease almost doubled between 1990 and 1999. 3 The average cost of treating ESRD in the UK is approximately d20 802/patient/year. 4 Any interventions that might prevent or delay the onset of ESRD in patients with type II diabetes would lead to major cost savings.
The Irbesartan in Diabetic Nephropathy Trial (IDNT) was a multicenter, double-blind, placebocontrolled study that randomized 1715 hypertensive patients with type II diabetes and proteinuria to treatment with irbesartan, amlodipine or standard blood pressure control alone. The primary composite endpoint was the development of doubling of serum creatinine concentration (DSC), ESRD or death from any cause. 5 Patients were followed up for a mean duration of 2.6 years. Irbesartan treatment resulted in a 23% (P ¼ 0.006) reduction in the combined endpoint of death, ESRD and DSC vs amlodipine, and a 20% reduction (P ¼ 0.02) vs the control treatment arm. The differences in outcomes were not explained by differences in blood pressure control seen in each treatment arm. A model has been developed to extrapolate the results of IDNT and project long-term clinical and cost outcomes. This model has previously been applied to the Belgian, French, German and United States settings. [6] [7] [8] These studies demonstrated that the mean time free from ESRD in the irbesartan-treated cohort was around 8.2 years, compared to 6.8 years for the amlodipine and 6.9 years for the control groups. Moreover, simulated long-term treatment with irbesartan was associated with a lower incidence of ESRD than amlodipine or control. At 10 years, the cumulative incidences of ESRD were 36, 49, and 45% in the irbesartan, amlodipine and control treatment arms, respectively. The projected life expectancy secondary to delay in ESRD was greater with irbesartan.
The aim of the current study was to adapt this model to the UK setting in order to compare the 10-year costs (costs of study medications þ ESRD treatment costs) and 10-year projected improvements in life expectancy due to avoidance or delay of ESRD in patients with hypertension, type II diabetes and overt nephropathy with either irbesartan, amlodipine, or standard blood pressure control alone. Blood pressure was controlled to a target of p135/ 85 mmHg with medications except ACE inhibitors, other calcium channel blockers or angiotensin receptor blockers. A 10-year period was chosen in order to capture the effects of delayed ESRD on changes in costs and life expectancy, while remaining confident that our long-term projections would be robust. We restricted the current analysis to the treatments assessed in the IDNT as there are few direct clinical comparisons between angiotensin II receptor blockers and ACE inhibitors.
Subjects and methods

Model structure
A detailed description of the model structure and methodology has been published elsewhere. 6, 7 A brief overview is provided here. A Markov model described the course of disease of a simulated cohort of patients with type II diabetes and hypertension as they progressed from overt nephropathy to DSC, ESRD (treated with either dialysis or renal transplantation) and death ( Figure 1 ). Markov models are a standard method for simulating the course of longterm, progressive diseases, and have been used extensively in chronic diseases like diabetes. [9] [10] [11] Three treatment choices were simulated, based upon the treatment arms of IDNT: irbesartan 300 mg per day, amlodipine 10 Health economics of irbesartan in diabetic nephropathy in the UK AJ Palmer et al calcium channel blockers). Other antihypertensive drugs were permitted in all arms to achieve the target blood pressure (p135/85 mmHg). Probabilities of progressing from the initial baseline state of IDNT (overt nephropathy) to DSC, ESRD, and death were taken from the IDNT, and have been detailed previously. [6] [7] [8] Transitional probabilities for the first 3 years of the model were obtained from the actual number of annual events in the IDNT clinical trial. For the next 7 years of the simulation, an average of probabilities across those first 3 years was used for each arm.
As no studies have been published comparing the effects of irbesartan, amlodipine and standard blood pressure control in ESRD patients, we conservatively assumed that when a patient developed ESRD during the simulation the probabilities of death or changing between dialysis and renal transplant states were independent of treatment arm. These probabilities were derived from UK-specific ESRD management and outcomes data ( Table 1) . 2 A National Health Service (NHS) payer perspective was taken for all the costs used in this simulation. Costs of medications and ESRD were assessed for patients in all three treatment arms. Costs that were similar between the treatment arms (eg visits to the general practitioner, cardiovascular events, urinary albumin monitoring and other investigations) were excluded from the analysis, 5 as we were interested in assessing the incremental costs only. Therefore, costs for patients in the states 'overt nephropathy' and 'DSC' included study drugs and concomitant antihypertensive agents. Costs for patients in the ESRD states included costs of dialysis or transplantation.
Study drug medication costs were determined using exposure time by dose in each treatment arm of the IDNT study ( Table 2 ). The cost of each dose was calculated from the British National Formulary. 12 The acquisition costs of medications were assumed to remain constant over the 10-year simulation period. We therefore did not take into account the possibility that medications may become cheaper in the future due to loss of patent protection -a conservative approach that overestimates the costs of irbesartan in the future, and may underestimate any cost savings that could be expected. Exposure to other antihypertensive medications in each treatment arm was used to calculate the total costs of concomitant medications. For each therapeutic class of adjunctive antihypertensive, the price of the drug which is currently most prescribed was utilized. Renal replacement therapy costs (kidney transplantation and maintenance therapy, and dialysis, weighted by the percentages receiving haemodialysis and peritoneal dialysis) were taken from published UK-specific sources (Table 2 ). In the base-case analysis, a value of d21 456/patient/year for the cost of dialysis was used, although reported values varied between d20 247 and d35 000/patient/ year. [13] [14] [15] [16] The upper and lower limits were used in sensitivity analysis. 'transplant' to 'death' Probability ¼ annual transition probability; 'year' refers to year of model simulation. A period of 10 years was used in the base-case analysis. In the sensitivity analysis results were also projected up to 25 years. Discounting was performed in accordance with current National Institute for Clinical Excellence guidelines using rates of 6.0% per annum for future costs, and 1.5% for future clinical benefits. 17 One-way sensitivity analysis was performed on total costs by varying each probability and cost parameter by710% one at a time while holding all other parameters constant, so as to rank the order of their impact. Sensitivity analysis was performed on the assumed duration of the effect of irbesartan, with ranges between 3 years (approximately the withintrial effects) and 10 years (assuming the continued effect of irbesartan). As an extremely conservative assumption for this sensitivity analysis, it was assumed that the probabilities would return to those of the control group after the 3-year trial period in all treatment arms (ie only the within-trial effects of irbesartan and amlodipine were considered).
Further sensitivity analyses were performed on the annual costs of dialysis, the annual costs of irbesartan and its effectiveness, and the time horizon of the analysis.
Results
After 10 years, mean total costs (medication costs þ ESRD treatment costs) were d20 882 for the irbesartan treatment group, d27 417 for the amlodipine treatment group, and d24 642 for patients treated with standard blood pressure control alone (Figure 2 ). Cost savings due to avoided/delayed ESRD were evident after 3 years compared to the amlodipine group, and after 4 years compared to the placebo group. Cost savings after 10 years were d5125 for irbesartan vs amlodipine, and d2919 for irbesartan vs control. Breakdown of the 10-year figure showed that the costs of patients who developed ESRD contributed the vast majority (85-94%), while the costs of amlodipine and irbesartan made up only 8 and 5% of the 10-year expenditure, respectively (Table 3) .
Reduction in progression to DSC and ESRD with irbesartan led to projected improvements in undiscounted life expectancy (discounted life expectancy shown in brackets) due to delayed or avoided ESRD of 0.08 (0.07) years and 0.23 (0.21) years vs amlodipine and control, respectively.
One-way sensitivity analysis of the total 10-year costs revealed that the parameter with the greatest single impact was the annual costs of dialysis. In the unlikely case that the annual costs of dialysis in the UK fell below d3000 (compared to d21 456 used in the base-case analysis and d20 245 identified as the lower limit of the range reported in the literature), irbesartan would no longer be cost saving compared to standard blood pressure control alone. On the other hand, if the annual costs of dialysis were d35 000 (the upper limit of the range found reported in the literature), the 10-year savings with irbesartan would increase to d10 150 and d6433 vs amlodipine or control, respectively. The annual cost of irbesartan had the seventh greatest impact on 10-year costs. The annual cost of irbesartan treatment would have to be higher than d900 per patient (compared to the current base-case cost of d237) to produce an overall cost increase compared to standard antihypertensive therapy alone (or d1303 compared to amlodipine).
Under the conservative assumption that only the within-trial (first 3 years) effects of irbesartan and amlodipine were considered (after which transition probabilities corresponded to those of the control arm), 10-year costs were d37 329 in the irbesartan group, d42 716 for amlodipine and d38 519 in the control group. Thus, even with very conservative assumptions about the long-term effectiveness of the medications, irbesartan remained cost saving compared to amlodipine and control.
If 20% higher rates of progression to DSC and ESRD are taken, irbesartan remained cost saving over 10 years compared to both amlodipine and control treatment arms, and by projecting to a 25-year time horizon, cost savings due to avoided ESRD increased to d9176 and d4978 vs amlodipine or control, respectively.
When a 25-year time horizon was used in the analysis, the projected cost savings per patient increased to d9176 and d4978 for irbesartan vs amlodipine or control, respectively (Figure 2 ). Improvements in projected life expectancy were also increased to 0.38 years (discounted life expectancy 0.31) and 0.70 years (0.58) for irbesartan vs amlodipine or control, respectively.
Discussion
IDNT showed that treatment with irbesartan is associated with delayed onset of ESRD compared to amlodipine and control and a reduced cumulative incidence of ESRD in hypertensive Type II diabetic nephropathy with associated projected improvements in life expectancy. [6] [7] [8] The present modelling study demonstrated that the reduction in progression to DSC and ESRD associated with irbesartan treatment leads to cost savings compared to treatment with amlodipine or control. Cost savings with irbesartan treatment instead of amlodipine or standard blood pressure control alone begin to occur after 3-4 years of therapy.
The results of this modelling study were robust under a wide range of plausible assumptions about the long-term effectiveness of drug therapy and costs of complications and medications, even in the extreme case assuming no effect of irbesartan or amlodipine after the 3-year trial period. This sensitivity analysis indicates that the conclusions of the study would probably still apply in a real-life setting, even taking into account the difference between efficacy in a clinical trial compared to standard UK clinical practice.
Multifactorial interventions that improve blood pressure, glycaemic control, lipid profiles and screening rates have demonstrated reductions in complications, improvements in other patient outcomes and were either cost saving or cost-effective in the management of type II diabetes. [18] [19] [20] The combination of these interventions with irbesartan may lead to further improvements in clinical outcome.
Both losartan and irbesartan have been demonstrated to be cost saving in other studies. The results of our analyses are consistent with other cost studies investigating the treatment of type II diabetes patients with nephropathy and hypertension with angiotensin-2 receptor blockers. Treatment with losartan in the United States and European settings led to reductions in ESRD incidence and to cost savings, compared to standard blood pressure control. 21, 22 Due to between-country variations in costs of healthcare resources and clinical outcomes like mortality rates in dialysis patients, country-specific analyses are recommended. 23 Our study results are also consistent with other costing analyses investigating the impact of the IDNT interventions in US, Belgian, French and German settings, all of which demonstrated cost savings vs amlodipine and control. [6] [7] [8] Irbesartan treatment in this patient group also led to long-term cost savings in a UK setting, where UK-specific costs of medications, ESRD outcomes and cost data were taken into account.
There are some limitations in our modelling study. The data used were derived from IDNT and applied whenever possible. This was done under the assumption that the results from a multicentre, multinational clinical trial would apply equally in clinical practice in the UK. Taking this into consideration and assuming a 20% higher rate of progression to DSC and ESRD with irbesartan in routine clinical practice, this still led to a cost saving compared to amlodipine or control.
IDNT investigated the effects of irbesartan, amlodipine or placebo, independent of blood pressure control. In the three treatment arms, blood pressure at baseline was similar. During the study followup, there was no significant difference in mean arterial blood pressure between the amlodipine and irbesartan groups, but the control group had a mean arterial blood pressure 3.3 mmHg higher. The differences in outcomes between the active groups are unlikely to be explained by differences in blood pressure control. When an adjustment was made for the differences in blood pressure control between the irbesartan and placebo groups, the magnitude of renal benefit afforded by irbesartan did not decrease significantly. 5 Patients included in IDNT had type II diabetes, hypertension and advanced proteinuria, and as such these results should only be taken in this context and not be extrapolated to patients with type II diabetes with less severe renal disease, or to those only with hypertension. While the cardiovascular event rates were not significantly different in each treatment arm of the IDNT, it is possible that the event rates would differ in other hypertensive patient groups, 24 and inclusion of cardiovascular events and their associated costs may have an impact on health economic outcomes in broader patient groups.
We were unable to compare our results to outcomes of treatment with ACE inhibitors, betablockers or other angiotensin-2 receptor blockers, because to date no direct clinical comparisons have been published in type II diabetic nephropathy. A modelling study performed in the UK setting for patients with type I diabetes and nephropathy demonstrated that treatment with the ACE inhibitor captopril (25 mg three times a day) would lead to discounted cost savings of d953 per patient over a 4-year period. 25 These data suggest that ACE inhibitor treatment has an important impact on costs at least for type I diabetic patients and underscores the need for head to head clinical comparisons between these drugs and angiotensin-2 receptor blockers.
In conclusion, this modelling study demonstrates that irbesartan therapy leads to a reduction in 10-year treatment costs of type II diabetic patients in the UK compared to amlodipine or standard antihypertensive therapy alone. These findings were robust under a wide range of plausible assumptions relating to treatment efficacy.
